Trial Profile
Comparison Fenofibrate, Rosiglitazone, or Weight Loss to Decrease Cardiovascular Risk in Insulin Resistant Dyslipidemic Individuals.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fenofibrate (Primary) ; Rosiglitazone (Primary)
- Indications Hypertriglyceridaemia; Insulin resistance
- Focus Therapeutic Use
- 09 May 2016 New trial record